Best High Tech Stocks To Invest In Right Now

Netflix may have surged 110 percent so far this year, but World Wrestling Entertainment (WWE) has been giving the streaming giant a run for its money and market watchers believe the stock will continue to clean house.

Shares of WWE rallied 3 percent Friday as Morgan Stanley raised its price target on the stock to $100 from $58. As WWE was trading around $76 on Friday morning, this means that analysts are predicting another 30 percent upside for the name.

Oppenheimer technician Ari Wald is also bullish on WWE and believes the stock is about to soar even higher than the 152 percent it has already surged this year.

“This is a great example of momentum in markets,” he said Thursday on CNBC’s “Trading Nation.” “All of the academic research shows that stocks with high risk-adjusted returns over the previous year usually continue to be the leaders over the coming year, and we like momentum.”

Best High Tech Stocks To Invest In Right Now: Array BioPharma Inc.(ARRY)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Array Biopharma (ARRY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Array Biopharma Inc (NASDAQ:ARRY) traded down 7.2% on Friday . The company traded as low as $13.48 and last traded at $13.98. 4,906,836 shares changed hands during trading, an increase of 68% from the average session volume of 2,921,348 shares. The stock had previously closed at $15.06.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Array Biopharma (ARRY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Shares of Array Biopharma Inc (NASDAQ:ARRY) have received an average rating of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $23.57.

  • [By Motley Fool Transcribers]

    Array Biopharma Inc (NASDAQ:ARRY)Q4 2018 Earnings Conference CallAug. 14, 2018, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Array Biopharma Inc (NASDAQ:ARRY) CEO Ron Squarer sold 184,253 shares of the stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $17.96, for a total transaction of $3,309,183.88. Following the completion of the transaction, the chief executive officer now owns 289,456 shares of the company’s stock, valued at $5,198,629.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Best High Tech Stocks To Invest In Right Now: TeleNav Inc.(TNAV)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Telenav (TNAV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    ValuEngine upgraded shares of Telenav (NASDAQ:TNAV) from a sell rating to a hold rating in a research note published on Saturday.

    Several other equities research analysts also recently issued reports on TNAV. BidaskClub upgraded Telenav from a sell rating to a hold rating in a report on Friday. Zacks Investment Research upgraded Telenav from a sell rating to a hold rating in a report on Thursday, April 5th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $11.17.

  • [By Stephan Byrd]

    Telenav Inc (NASDAQ:TNAV) has received a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $11.17.

Best High Tech Stocks To Invest In Right Now: Approach Resources Inc.(AREX)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Approach Resources (AREX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Approach Resources (AREX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Approach Resources Inc. (NASDAQ:AREX) hit a new 52-week low during trading on Thursday . The company traded as low as $2.02 and last traded at $2.04, with a volume of 2875 shares trading hands. The stock had previously closed at $2.08.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Approach Resources (AREX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Media headlines about Approach Resources (NASDAQ:AREX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Approach Resources earned a coverage optimism score of 0.02 on Accern’s scale. Accern also gave press coverage about the energy company an impact score of 46.8987147373518 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Best High Tech Stocks To Invest In Right Now: Eaton Vance Limited Duration Income Fund(EVV)

Advisors’ Opinion:

  • [By Logan Wallace]

    Eaton Vance Ltd Duration Income Fund (NYSEAMERICAN:EVV) was the recipient of a large increase in short interest in September. As of September 14th, there was short interest totalling 61,700 shares, an increase of 154.4% from the August 31st total of 24,249 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 199,358 shares, the short-interest ratio is currently 0.3 days.

Best High Tech Stocks To Invest In Right Now: McKesson Corporation(MCK)

Advisors’ Opinion:

  • [By Motley Fool Transcribing]

    McKesson (NYSE:MCK) Q3 2019 Earnings Conference CallJan. 31, 2019 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By ]

    Robbins made the comment during his presentation at the Sohn conference, adding that he was refuting speculation that he was opposed to the deal. Glenveiw Capital owns a 1.2% of Cigna, according to FactSet. Robbins added that he likes Express Scripts, CVS (CVS) and McKesson Corp. (MCK) .

  • [By ]

    It may be unhealthy to trade drug stocks Friday. The word on Wall Street is to not expect too much from President Trump’s speech on drug prices. That means expect the unexpected, and prepare for a volatility spike in key healthcare names such as Express Scripts (ESRX) , CVS Health (CVS) , Endo International (ENDP) , Mallinckrodt (MNK) , McKesson (MCK) and Cardinal Health (CAH) .

    Reports TheStreet’s Bill Meagher: “Evercore ISI may be an outlier as its analysts anticipate that recent speeches by officials from the Food and Drug Administration, Health and Human Services and Centers for Medicare & Medicaid Services may have telegraphed the Trump administration’s willingness to move beyond loud talk and tweets into policy discussions. In those tweets and in talks with his cabinet, Trump has been critical of the pharmaceutical sector and its pricing of prescription drugs, famously saying on at least two occasions that companies are “getting away with murder.”

  • [By Lisa Levin]

    McKesson Corporation (NYSE: MCK) reported weaker-than-expected earnings for its fiscal fourth quarter.

    The company posted adjusted earnings of $3.49 per share on revenue of $51.63 billion. However, analysts were expecting earnings of $3.56 per share on revenue of $51.25 billion.

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Best Buy Co., Inc. (NYSE: BBY) to report quarterly earnings at $0.74 per share on revenue of $8.73 billion before the opening bell. Best Buy shares rose 0.07 percent to $76.00 in after-hours trading.
    Analysts expect Ross Stores, Inc. (NASDAQ: ROST) to post quarterly earnings at $1.07 per share on revenue of $3.54 billion. Ross Stores shares gained 0.12 percent to $82.71 in after-hours trading.
    Williams-Sonoma, Inc. (NYSE: WSM) reported stronger-than-expected results for its first quarter. The company also raised its FY18 earnings and sales guidance. Williams-Sonoma shares climbed 14.88 percent to $56.50 in the after-hours trading session.
    Before the markets open, Medtronic plc (NYSE: MDT) is projected to report quarterly earnings at $1.39 per share on revenue of $8.00 billion. Medtronic shares rose 1.08 percent to $86.18 in after-hours trading.
    Analysts are expecting McKesson Corporation (NYSE: MCK) to have earned $3.56 per share on revenue of $51.25 billion in the latest quarter. McKesson will release earnings before the markets open. McKesson shares gained 0.27 percent to close at $146.83 on Wednesday.
    L Brands Inc (NYSE: LB) reported weaker-than-expected earnings for its first quarter. The company issued weak second quarter and FY18 earnings guidance. L Brands shares dropped 4.85 percent to $32.40 in the after-hours trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Max Byerly]

    Nomura Asset Management Co. Ltd. boosted its stake in shares of McKesson Co. (NYSE:MCK) by 3.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,772 shares of the company’s stock after purchasing an additional 1,411 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in McKesson were worth $5,305,000 at the end of the most recent reporting period.

Leave a Reply

Your email address will not be published. Required fields are marked *